With the average cost to bring a new drug to market surging upwards of $2.5 billion, our client
wanted to get in front of any mentions of trial drugs before they are officially available. This is
the story of how GroupSense partners with a global pharmaceutical company to fight back against IP fraud.
GroupSense identified a syndicate claiming to have access to name-brand medications. Whether the activities are the result physical theft of medication, or manufacturing of counterfeit drugs, there could be negative impact for the client.
Armed with this intel, our customer can quickly take action to prevent further activities from this
group. Understanding how a threat actor operates empowers the client to modify their own processes in the future to prevent recurrences.
“GroupSense delivers the best intel we’ve ever seen from any vendor.”